NIH Chief Stresses Economic Impact of Federal Biomedical Funding

Cancer and certain types of mental illness are diseases that appear ripe for research breakthroughs, according to Francis Collins, who just marked his sixth month as director of the National Institutes of Health.

“I’m always loath to say what’s on the brink of some big breakthrough,” says Collins, who met with local reporters while attending the annual meeting of the American Association for the Advancement of Science—which is in San Diego for the first time since the AAAS was founded in 1848. Yet Collins, who previously led the Human Genome Project, says advances in genomics and the power of genetic sequencing technologies are opening the possibility of new therapies in cancer, as well as for schizophrenia, autism, and bipolar disorders—diseases with strong genetic components.

“I would hope in another five years that we would have the capability to have the genome of your tumor completely analyzed—and then go through the list of drugs that are available” to determine which anti-tumor drug would be most effective. Collins says using genomics to assess how genetic variations affect each patient’s individual response to different drugs is an example of the growing field of pharmacogenomics, and represents another aspect of the revolution that’s underway.

Collins says cancer is a disease of the genome, and federal funding for biomedical research is not only advancing on a cure but also helping to sustain the nation’s economic recovery. Of $10 billion in stimulus funding to be spent over two years on biomedical research, Collins says about $4.5 billion has been allocated throughout the country so far.

Some additional details, courtesy of the NIH director:

—Of the $4.5 billion in current economic recovery and stimulus funding, the NIH directed $126 million to researchers in San Diego County. Including the stimulus funding, the NIH provided about $920 million in funding for biomedical research in San Diego County during the current fiscal year. NIH grants are supporting 1,180 scientists at 92 organizations throughout the county. “San Diego is famous for being on the high end of innovation, both at the academic centers and at the research institutes,” Collins says.

—The NIH also has created a pilot that uses federal stimulus funding to

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.